Why carry out this study?

Ixekizumab has a rapid onset of action, high levels of skin clearance, and results in improvements in quality of life in patients with moderate-to-severe psoriasis, including plaque, erythrodermic, or generalized pustular psoriasis.

We hypothesized that rapid clinical responses to ixekizumab would result in better improvements in quality of life than slower responses.

What was learned from the study?

Patients who had rapid improvements in clinical symptoms of psoriasis (Psoriasis Area and Severity Index) had better improvements in quality of life (Dermatology Life Quality Index) and bothersome itch symptoms (Itch Numeric Rating Scale).

Treatments that provide rapid onset and complete or almost complete skin clearance may provide better quality-of-life outcomes for patients with moderate-to-severe psoriasis.